Ethic Inc. Increases Holdings in IQVIA Holdings Inc. $IQV

Ethic Inc. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 39.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,391 shares of the medical research company’s stock after buying an additional 9,498 shares during the period. Ethic Inc.’s holdings in IQVIA were worth $5,258,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Caliber Wealth Management LLC KS raised its holdings in shares of IQVIA by 47.2% during the 2nd quarter. Caliber Wealth Management LLC KS now owns 10,493 shares of the medical research company’s stock valued at $1,654,000 after buying an additional 3,363 shares in the last quarter. Rehmann Capital Advisory Group purchased a new position in shares of IQVIA during the 2nd quarter valued at about $223,000. Brookstone Capital Management raised its holdings in shares of IQVIA by 9.2% during the 2nd quarter. Brookstone Capital Management now owns 3,063 shares of the medical research company’s stock valued at $483,000 after buying an additional 259 shares in the last quarter. Terra Alpha Investments LLC raised its holdings in shares of IQVIA by 25.8% during the 2nd quarter. Terra Alpha Investments LLC now owns 9,616 shares of the medical research company’s stock valued at $1,515,000 after buying an additional 1,972 shares in the last quarter. Finally, D.A. Davidson & CO. increased its stake in IQVIA by 2.2% in the 2nd quarter. D.A. Davidson & CO. now owns 19,613 shares of the medical research company’s stock worth $3,091,000 after purchasing an additional 413 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQV opened at $220.13 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $225.91. The stock has a market capitalization of $37.42 billion, a PE ratio of 31.86, a price-to-earnings-growth ratio of 2.39 and a beta of 1.32. The stock’s 50 day moving average price is $193.88 and its 200-day moving average price is $170.74.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company posted $2.64 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on IQV shares. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Redburn Partners set a $214.00 price target on IQVIA in a research note on Wednesday, September 3rd. Robert W. Baird lifted their price target on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. Mizuho lifted their price target on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $234.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.